Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Diabetic foot ulcers (DFUs) often pose a treatment problem. Bioengineered skin substitutes have been reported to result in accelerated diabetic wound healing. The purpose of this clinical trial was to evaluate the efficacy and safety of the autologous fibroblast-hyaluronic acid complex for treating DFUs. Method: A stratified, randomised, controlled, multicentre study was carried out. Patients with DFUs were allocated to either a treatment group with grafting of an autologous fibroblast-hyaluronic acid complex or a control group with non-adherent foam dressing. Except for application of the fibroblast complex, treatment of the study ulcers was identical for patients in both groups. The maximum follow-up period for each patient was 12 weeks. Results: Complete ulcer healing was achieved in 84% (26/31 patients) of the treatment group and 34% (11/32 patients) of the control group (p<0.05). The times required for complete healing were 36.4±17.6 and 48.4±13.1 days in the treatment and control groups, respectively (p<0.05). No adverse events related to treatment occurred. Conclusion: These results indicate that autologous fibroblast-hyaluronic acid complex may offer a safe and effective treatment for DFUs.

Original languageEnglish
Pages (from-to)521-530
Number of pages10
JournalJournal of wound care
Volume23
Issue number11
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Diabetic Foot
Hyaluronic Acid
Randomized Controlled Trials
Fibroblasts
Control Groups
Therapeutics
Ulcer
Artificial Skin
Bandages
Wound Healing
Multicenter Studies
Clinical Trials
Safety

Keywords

  • Diabetic foot
  • Diabetic foot ulcer
  • Fibroblast
  • Hyaluronic acid
  • Wound healing

ASJC Scopus subject areas

  • Nursing (miscellaneous)
  • Fundamentals and skills
  • Medicine(all)

Cite this

Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers. / You, Hijin; Han, Seung-Kyu; Rhie, J. W.

In: Journal of wound care, Vol. 23, No. 11, 01.01.2014, p. 521-530.

Research output: Contribution to journalArticle

@article{b4703359e1a342b0860f107bf457dbf0,
title = "Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers",
abstract = "Objective: Diabetic foot ulcers (DFUs) often pose a treatment problem. Bioengineered skin substitutes have been reported to result in accelerated diabetic wound healing. The purpose of this clinical trial was to evaluate the efficacy and safety of the autologous fibroblast-hyaluronic acid complex for treating DFUs. Method: A stratified, randomised, controlled, multicentre study was carried out. Patients with DFUs were allocated to either a treatment group with grafting of an autologous fibroblast-hyaluronic acid complex or a control group with non-adherent foam dressing. Except for application of the fibroblast complex, treatment of the study ulcers was identical for patients in both groups. The maximum follow-up period for each patient was 12 weeks. Results: Complete ulcer healing was achieved in 84{\%} (26/31 patients) of the treatment group and 34{\%} (11/32 patients) of the control group (p<0.05). The times required for complete healing were 36.4±17.6 and 48.4±13.1 days in the treatment and control groups, respectively (p<0.05). No adverse events related to treatment occurred. Conclusion: These results indicate that autologous fibroblast-hyaluronic acid complex may offer a safe and effective treatment for DFUs.",
keywords = "Diabetic foot, Diabetic foot ulcer, Fibroblast, Hyaluronic acid, Wound healing",
author = "Hijin You and Seung-Kyu Han and Rhie, {J. W.}",
year = "2014",
month = "1",
day = "1",
doi = "10.12968/jowc.2014.23.11.521",
language = "English",
volume = "23",
pages = "521--530",
journal = "Journal of wound care",
issn = "0969-0700",
publisher = "MA Healthcare Ltd",
number = "11",

}

TY - JOUR

T1 - Randomised controlled clinical trial for autologous fibroblast-hyaluronic acid complex in treating diabetic foot ulcers

AU - You, Hijin

AU - Han, Seung-Kyu

AU - Rhie, J. W.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Objective: Diabetic foot ulcers (DFUs) often pose a treatment problem. Bioengineered skin substitutes have been reported to result in accelerated diabetic wound healing. The purpose of this clinical trial was to evaluate the efficacy and safety of the autologous fibroblast-hyaluronic acid complex for treating DFUs. Method: A stratified, randomised, controlled, multicentre study was carried out. Patients with DFUs were allocated to either a treatment group with grafting of an autologous fibroblast-hyaluronic acid complex or a control group with non-adherent foam dressing. Except for application of the fibroblast complex, treatment of the study ulcers was identical for patients in both groups. The maximum follow-up period for each patient was 12 weeks. Results: Complete ulcer healing was achieved in 84% (26/31 patients) of the treatment group and 34% (11/32 patients) of the control group (p<0.05). The times required for complete healing were 36.4±17.6 and 48.4±13.1 days in the treatment and control groups, respectively (p<0.05). No adverse events related to treatment occurred. Conclusion: These results indicate that autologous fibroblast-hyaluronic acid complex may offer a safe and effective treatment for DFUs.

AB - Objective: Diabetic foot ulcers (DFUs) often pose a treatment problem. Bioengineered skin substitutes have been reported to result in accelerated diabetic wound healing. The purpose of this clinical trial was to evaluate the efficacy and safety of the autologous fibroblast-hyaluronic acid complex for treating DFUs. Method: A stratified, randomised, controlled, multicentre study was carried out. Patients with DFUs were allocated to either a treatment group with grafting of an autologous fibroblast-hyaluronic acid complex or a control group with non-adherent foam dressing. Except for application of the fibroblast complex, treatment of the study ulcers was identical for patients in both groups. The maximum follow-up period for each patient was 12 weeks. Results: Complete ulcer healing was achieved in 84% (26/31 patients) of the treatment group and 34% (11/32 patients) of the control group (p<0.05). The times required for complete healing were 36.4±17.6 and 48.4±13.1 days in the treatment and control groups, respectively (p<0.05). No adverse events related to treatment occurred. Conclusion: These results indicate that autologous fibroblast-hyaluronic acid complex may offer a safe and effective treatment for DFUs.

KW - Diabetic foot

KW - Diabetic foot ulcer

KW - Fibroblast

KW - Hyaluronic acid

KW - Wound healing

UR - http://www.scopus.com/inward/record.url?scp=84911417493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911417493&partnerID=8YFLogxK

U2 - 10.12968/jowc.2014.23.11.521

DO - 10.12968/jowc.2014.23.11.521

M3 - Article

VL - 23

SP - 521

EP - 530

JO - Journal of wound care

JF - Journal of wound care

SN - 0969-0700

IS - 11

ER -